89bio (NASDAQ:ETNB) shares are trading higher on Wednesday after the company's Phase 2b ENLIVEN trial of pegozafermin in NASH achieved statistical significance on both primary histology endpoints.

ENLIVEN is a multicenter, randomized, double-blind, placebo-controlled Phase 2b trial designed to evaluate the safety and efficacy of weekly or every-two-week dosing of pegozafermin for the treatment of patients with fibrosis stage F2 - F3 NASH and NAS ≥ 4 for 48 weeks.

Pegozafermin continued to demonstrate a favorable safety and tolerability profile consistent with prior studies. Across dose groups, the most frequently reported treatment-related adverse events (AEs) were Grade 1 or 2 gastrointestinal events (diarrhea, nausea and increased appetite) most of which were mild to moderate in nature. Rates of treatment-related AEs observed were less frequent with the Q2W dosing regimen.

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases

Price Action: 89bio has a 52-week high of $15.5 and a 52-week low of $2.03.

89bio shares are up 28.3% at $14.03 at the time of writing, according to Benzinga Pro.